

## The Trendlines Group Reports Third Quarter 2019 Results

**Misgav, Israel and Singapore**, 7 November 2019 – The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries, “**Trendlines**” or the “**Group**”) (SGX: 42T; OTCQX: TRNLY), a leading Israel- and Singapore-based investment and innovation commercialization company focused on early-stage, high-growth, innovation-based medical and agricultural technologies, announced its financial results for the third quarter of 2019 ended 30 September 2019 (“**Q3 2019**”).

### Third Quarter 2019 Highlights

*As at 30 September 2019 unless otherwise noted*

#### Group Financials

- Fair value of portfolio: US\$94.6 million (31.12.18: US\$97.2 million)
- Total current assets: US\$15.0 million (31.12.18: US\$11.8 million)
- Book value: US\$89.8 million (31.12.18: US\$86.4 million)
- Operating general and administrative expenses: US\$1.7 million (Q3 2018: US\$1.8 million)
- Net loss: US\$2.6 million (Q3 2018: Net gain of US\$3.1 million)
- NAV per share: US\$0.13 (31.12.18: US\$0.15)

#### Q3 2019 Corporate/Business Developments

- Trendlines completed an US\$8 million placement to Librae Holdings Ltd. (“Librae Holdings”)
- Trendlines announced a Rights Issue
- Trendlines welcomed its newest agtech Portfolio Company, EcoPhage Ltd., the second investment by the Bayer Trendlines Ag Innovation Fund
- The Company incorporated Trendlines Labs-generated company, Szone Medical Ltd., as a subsidiary in Trendlines Medical Singapore Pte. Ltd.’s incubator
- MetoMotion Ltd. received US\$1.5 million investment from a Netherlands-based strategic partner
- ApiFix Ltd. received approval from the United States Food and Drug Administration (“FDA”) for its MID-C System for treatment of scoliosis in adolescents
- OrthoSpin Ltd. received FDA clearance for its robotic external fixation system
- Fidmi Medical Ltd. signed a collaboration agreement with U.S.-based Coap Tech Inc.
- FruitSpec Ltd. closed US\$4 million investment round
- FDA designated Leviticus Cardio Ltd.’s FiVAD as a “breakthrough device”

- Trendlines received conditional commitments of up to US\$22 million for its new Singapore-based venture fund, Trendlines Agrifood Pte. Ltd. (“Agrifood Fund”)

#### Post Q3 2019 Developments

- Fidmi Medical Ltd. received FDA clearance for its low-profile enteral feeding device
- Gordian Surgical Ltd. raised US\$3 million for the commercialization of its access-closure system

Chairman and CEO Todd Dollinger commented, “In this announcement we have described three companies that received FDA clearance and three other companies that raised a total of US\$8.5 million in new capital; we are well on our way to a record year for our portfolio companies. These achievements confirm our commitment to building the value of our portfolio companies and bringing them closer to commercialization opportunities.”

#### Q3 2019 Financial Results

The fair value of Trendlines’ portfolio was US\$94.6 million as at 30 September 2019, having decreased by approximately US\$1.0 million as compared to 30 June 2019. It should be noted that the portfolio value does not reflect all current portfolio companies, due to consolidation of seven Singapore-based portfolio companies that are treated as subsidiaries controlled by The Trendlines Group.

The main reasons for the Q3 2019 reduction in portfolio value are:

A decrease of approximately US\$5.3 million in the fair market value of various portfolio companies mainly as a result of the completion of fund-raising exercises at less favorable terms to the Company, the write-off of two companies, and general commercial or technological difficulties demonstrated in some portfolio companies in Q3 2019.

The decrease in fair market value of investments in portfolio companies was partially offset by:

An increase of US\$3.4 million from various portfolio companies based on factors such as the terms on which each portfolio company completed its fund-raising exercises.

Commenting on Trendlines’ third quarter results, Chairman and CEO Steve Rhodes said, “During Q3 2019 we completed an US\$8 million placement to Librae Holdings at a price of S\$0.1050 per placement share, which represents a premium of 34.6% over the then-prevailing price of S\$0.0780 for each share<sup>1</sup>. In September we announced

---

<sup>1</sup> The then-prevailing share price refers to the volume weighted share price based on trades done on the shares on the Catalist of the SGX-ST for the full market day on 19 July 2019 (being the last full

investment commitments for Trendlines' Singaporean Agrifood Fund. On 26 September 2019, the Company announced that it is undertaking a renounceable non-underwritten rights issue with an irrevocable commitment from Librae Holdings to, among others, fully subscribe for its entitlement under the rights issue."

"These recent events have all significantly strengthened the Company's balance sheet and ability to continue supporting and developing our portfolio companies."

For full financial information, see our announcement to the SGX: Unaudited Financial Statements for the three months and nine months ended 30 September 2019.

Management will record a presentation of the financial results and business developments for Q3 2019. Questions regarding the Q3 2019 financial results can be sent to [shira@trendlines.com](mailto:shira@trendlines.com) up until 8:00 a.m. on 10 November 2019. The recording will be available on the Trendlines' website by Thursday, 14 November 2019.

#### **About The Trendlines Group Ltd.**

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

-The End-

#### **Investor Contact Information**

Israel  
Shira Zimmerman, The Trendlines Group  
[shira@trendlines.com](mailto:shira@trendlines.com)  
Tel: +972.72.260.7000

Singapore  
Reyna MEI, Financial PR  
[reyna@financialpr.com.sg](mailto:reyna@financialpr.com.sg)  
Tel: +65.6438.2990

-----

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the

---

market day on which there were trades done on the shares prior to the date of the subscription agreement in relation to the placement).

“Sponsor”) in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalyst.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg))